SCHEMBL4531436

SCHEMBL4531436

C=CCc1c(CC)ccc2cc(C(=O)Nc3ccc(CN(C)C)cc3)c(=O)oc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
POLB P06746 3/20 0.55
TDP1 Q9NUW8 2/20 0.55
PLEC Q15149 1/20 0.55
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
TP53 P04637 2/20 0.48
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
HPGD P15428 2/20 0.46
PKM P14618 1/20 0.46
APEX1 P27695 1/20 0.46
PTPN7 P35236 1/20 0.46
BLM P54132 1/20 0.46
MCL1 Q07820 1/20 0.46
PTPN22 Q9Y2R2 1/20 0.46
KDM4E B2RXH2 7/20 0.46
ALDH1A1 P00352 6/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522924 0.88 MAOB (0.49) MAPTMEN1KMT2APOLBTDP1
SCHEMBL4523523 0.87 MAPT (0.53) MAPTMEN1KMT2APOLBTDP1
SCHEMBL3878896 0.87 MAPT (0.54) MAPTMEN1KMT2APOLBTDP1
SCHEMBL3880564 0.85 MAPT (0.77) MAPTMEN1KMT2APOLBTDP1
SCHEMBL4520996 0.81 TP53 (0.56) MAPTTP53MAOAMAOBCYP3A4
SCHEMBL3880339 0.78 S1PR1 (0.63) MAPTPOLBTP53MAOAMAOB
SCHEMBL28626506 0.77 AKR1C3 (0.60) MAPTMEN1KMT2APOLBTDP1
SCHEMBL3878880 0.77 S1PR1 (0.53) MAPTPOLBNPC1RAB9ATP53
SCHEMBL3881815 0.77 MAPT (0.50) MAPTMEN1KMT2APOLBTDP1
SCHEMBL4509778 0.76 S1PR1 (0.56) MAPTPOLBTP53MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318546-A1 Chromen-2-One Derivatives NOVARTIS AG (CH) 2009-12-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318546-A1 Chromen-2-One Derivatives CYP1A2, CYP4B1, CYP1B1 MAPT 3872/4885MEN1 759/4885KMT2A 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.